Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

Collaborative Group, RECOVERY; Horby, Peter; Pessoa-Amorim, Guilherme; Peto, Leon; E. Brightling, Christopher; Sarkar, Rahuldeb; Thomas, Koshy; Jeebun, Vandana; Ashish, Abdul; Tully, Redmond; Chadwick, David; Azhar Sharafat, Muhammad; Stewart, Richard; Rudran, Banu; Kenneth Baillie, J.; H Buch, Maya; C. Chappell, Lucy; Day, Jeremy; N Furst, Saul; Jaki, Thomas; Jeffery, Katie; Juszczak, Edmund; Shen Lim, Wei; Montgomery, Alan; Mumford, Andrew; Rowan, Kathy; Thwaites, Guy; Mafham, Marion; Haynes, Richard; Landray, Martin

doi:10.1101/2021.02.11.21249258

Public

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial

Published in medRxiv • Feb 11, 2021

Authors:

RECOVERY Collaborative Group

Peter Horby

Guilherme Pessoa-Amorim

Abstract

SUMMARY Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin (IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We evaluated the safety and efficacy of tocilizumab in adult patients admitted to hospital with COVID-19 with evidence...

Subject

Tocilizumab

Medicine

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!